natgillin/translations-raw huggingface dataset:
Kivexa contains a colouring called sunset yellow (E110), this may cause allergic reactions in some people.
Zdravilo Kivexa vsebuje barvilo sončno rumeno FCF (E110), ki lahko pri nekaterih osebah povzroči alergijske reakcije.
Kivexa contains abacavir (which is also an active substance in medicines such as Trizivir, Triumeq and Ziagen).
Zdravilo Kivexa vsebuje abakavir (ki je tudi zdravilna učinkovina v zdravilih, kot so zdravila Trizivir, Triumeq in Ziagen).
Kivexa contains abacavir (which is also an active substance in medicines such as Trizivir, Triumeq and Ziagen).
Zdravilo Kivexa vsebuje abakavir (ki je tudi zdravilna učinkovina zdravil Trizivir, Triumeq in Ziagen).
Kivexa contains abacavir and lamivudine, therefore any interactions identified for these individually are relevant to Kivexa.
Zdravilo Kivexa vsebuje abakavir in lamivudin, zato je katera koli interakcija, povezana s posamezno zdravilno učinkovino, relevantna tudi za zdravilo Kivexa.
Kivexa film-coated tablets are engraved with ‘GS FC2’ on one side.
Filmsko obložene tablete Kivexa imajo na eni strani odtisnjeno oznako GS FC2.
Kivexa is not recommended for use in patients with a creatinine clearance < 50 ml/min as necessary dose adjustment cannot be made (see section 5.2).
Zdravila Kivexa ni priporočljivo uporabljati pri bolnikih s kreatininskim očistkom < 50 ml/min, saj obvezno prilagajanje odmerka ni možno. (glejte poglavje 5.2).
Kivexa is used to treat HIV (human immunodeficiency virus) infection in adults, adolescents and in children weighing at least 25 kg.
Zdravilo Kivexa se uporablja za zdravljenje okužbe z virusom HIV (virusom humane imunske pomanjkljivosti) pri odraslih, mladostnikih in otrocih, ki tehtajo vsaj 25 kg.
Kivexa may cause side effects which could affect your ability to drive or use machines.
Zdravilo Kivexa lahko povzroči neželene učinke, ki lahko vplivajo na vašo sposobnost upravljanja vozil ali strojev.
Kivexa must be stopped without delay, even in the absence of the HLA-B*5701 allele, if an HSR is suspected.
Zdravljenje z zdravilom Kivexa je potrebno prekiniti brez odlašanja v primeru suma na HSR, tudi ob odsotnosti alela HLA-B*5701.
Kivexa should never be initiated in patients with a positive HLA-B*5701 status, nor in patients with a negative HLA-B*5701 status who had a suspected abacavir HSR on a previous abacavir- containing regimen. (e.g.
Zdravila Kivexa se nikdar ne sme uvesti bolnikom s pozitivnim HLA-B*5701 statusom; prav tako se ga ne sme uvesti bolnikom z negativnim HLA-B*5701 statusom, ki so imeli v preteklosti med uporabo sheme z abakavirjem sum na HSR na abakavir (npr.
Kivexa should not be taken with any other medicinal products containing lamivudine (see section 4.4).
Zdravila Kivexa se ne sme jemati z nobenim drugim zdravilom, ki vsebuje lamivudin (glejte poglavje 4.4).
Kivexa, Trizivir or Triumeq) again, as within hours you may experience a life-threatening lowering of your blood pressure or death.
Kivexa, Trizivir ali Triumeq), saj se vam lahko že v nekaj urah pojavi življenjsko ogrožujoče znižanje krvnega tlaka ali smrt.
Kivexa, Trizivir or Triumeq) again, as within hours you may experience a life-threatening lowering of your blood pressure or death.
Kivexa, Trizivir, Triumeq), saj se vam lahko že v nekaj urah pojavi življenjsko ogrožujoče znižanje krvnega tlaka ali smrt.
Kivexa, Trizivir, Triumeq) must never be re- initiated.
Kivexa, Trizivir, Triumeq) nikoli ne sme ponovno uvesti.
Kivexa, Ziagen, Triumeq) must never be re- initiated.
Kivexa, Ziagen, Triumeq) nikoli ne sme ponovno uvesti.
Klanteninformatiedienst voor EXUBERA Tel: 0800 3982372
EXUBERA Customer Care Centre Tel: 800 62451
KM %
338 (4,8 %)
KM %
487 (6,9 %)
KM %
7,8
KM = Kaplan-Meier; MIPI = Mantle Cell Lymphoma International Prognostic Index; NA = not applicable; ORR = overall response rate; PD = progressive disease; PFS = progression-free survival; PR= partial response; SCT = stem cell transplantation; SD = stable disease; SE = standard error. a The median was based on the KM estimate. b Range was calculated as 95% CIs about the median survival time. c The mean and median are the univariate statistics without adjusting for censoring. d The stratification variables included time from diagnosis to first dose (< 3 years and ≥ 3 years), time from last prior systemic anti-lymphoma therapy to first dose (< 6 months and ≥ 6 months), prior SCT (yes or no), and MIPI at baseline (low, intermediate, and high risk). e Sequential test was based on a weighted mean of a log-rank test statistic using the unstratified log-rank test for sample size increase and the unstratified log-rank test of the primary analysis.
NA = ni navedbe; ORR = stopnja celokupnega odziva; PD = napredovanje bolezni; PFS = preživetje brez napredovanja bolezni; PR = delni odziv; SCT = presaditev matičnih celic; SD = stabilna bolezen; SE = standardna napaka. a Mediana je temeljila na KM oceni. b Razpon je bil izračunan kot 95 % IZ-ja okrog mediane časa preživetja. c Povprečje in mediana sta univariatna statistična podatka brez prilagajanja za cenzuriranje. d Stratifikacijske spremenljivke so vključevale čas od postavitve diagnoze do prvega odmerka (< 3 leta in ≥ 3 leta), čas od zadnje predhodne sistemske antilimfomske terapije do prvega odmerka (< 6 mesecev in ≥ 6 mesecev), predhodna SCT (da ali ne) in MIPI v izhodišču (majhno, srednje in veliko tveganje). e Sekvenčni test je temeljil na statistiki utežnega povprečja testa log-rank z uporabo nestratificiranega testa log-rank za zvečanje velikosti vzorca in nestratificiranega testa log-rank primarne analize.
KM estimate of cumulative failure rate (%)
Čas do prveg zaradi srčne
Knob
odmerka
Know the Pen features Before use (Figure A)
Spoznajte značilnosti napolnjenega injekcijskega peresnika Pred uporabo (slika A)
Know the pre-filled syringe features
Spoznajte značilnosti napolnjene injekcijske brizge
Know your hepatitis B virus (HBV) infection status before starting Emtricitabine/Tenofovir disoproxil Zentiva.
Ugotovite stanje okužbe z virusom hepatitisa B (HBV) pred začetkom jemanja zdravila Emtricitabin/dizoproksiltenofovirat Zentiva.
Know your hepatitis B virus (HBV) infection status before starting Truvada.
Ugotovite stanje okužbe z virusom hepatitisa B (HBV) pred začetkom jemanja zdravila Truvada.
know your injection is complete when the grey part is visible.
Da je injiciranje končano, boste vedeli, ker bo sivi del viden.
Known active malignancies.
Ugotovljena aktivna maligna bolezen.
Known adverse reactions for metformin, that were not reported in patients who received Jentadueto are listed in Table 4.
Znani neželeni učinki metformina, o katerih niso poročali pri bolnikih, ki so jemali zdravilo Jentadueto, so navedeni v preglednici 4.
Known allergic reactions to mouse or hamster protein.
Znane alergijske reakcije na beljakovine miši ali hrčkov.
Known anaphylactic reactions to the active substance, hamster protein, or to any of the excipients listed in section 6.1.
Znana anafilaktična reakcija na zdravilno učinkovino, beljakovine hrčka ali katero koli pomožno snov, navedeno v poglavju 6.1.
Known bleeding diathesis except for acute coagulopathy related to sepsis
Znana nagnjenost h krvavitvam z izjemo akutne koagulopatije, povezane s sepso
Known congenital prolongation of the QTc-interval or any clinical condition known to prolong the QTc interval or QTc > 500 ms.
Znano prirojeno podaljšanje intervala QTc ali katerega drugega kliničnega stanja, za katerega je znano, da podaljšuje interval QTc ali QTc > 500 ms.
Known congenital prolongation of the QTc-interval or any clinical condition known to prolong the QTc interval.
Znano prirojeno podaljšanje intervala QTc ali katero koli klinično stanje, za katerega je znano, da podaljšuje interval QTc.
Known dihydropyrimidine dehydrogenase (DPD) deficiency.
Znano pomanjkanje dihidropirimidin dehidrogenaze (DPD).
Known gallbladder disease
Znana bolezen žolčnika
known haemorrhagic diathesis
znana hemoragična diateza,
Known hereditary or acquired predisposition for arterial thromboembolism, such as hyperhomocysteinaemia and antiphospholipid-antibodies (anticardiolipin-antibodies, lupus anticoagulant).
Znana dedna ali pridobljena nagnjenost k arterijski trombemboliji, kot so hiperhomocisteinemija in antifosfolipidna protitelesa (protitelesa proti kardiolipinu, lupusni antikoagulant).
Known hereditary or acquired predisposition for arterial thromboembolism, such as hyperhomocysteinaemia and antiphospholipid-antibodies (anticardiolipin-antibodies, lupus anticoagulant);
Znana dedna ali pridobljena nagnjenost k arterijski trombemboliji, kot sta hiperhomocisteinemija in antifosfolipidna protitelesa (antikardiolipinska protitelesa, lupusni antikoagulant).
Known hereditary or acquired predisposition for venous thromboembolism, such as APC- resistance (including Factor V Leiden), antithrombin-III-deficiency, protein C deficiency, protein S deficiency.
Znana dedna ali pridobljena nagnjenost k venski trombemboliji, kot so rezistenca na aktivirani protein C (APC; vključno s faktorjem V Leiden), pomanjkanje antitrombina-III, pomanjkanje proteina C, pomanjkanje proteina S.
Known hereditary or acquired predisposition for venous thromboembolism, such as APC-resistance (including Factor V Leiden), antithrombin-III-deficiency, protein C deficiency, protein S deficiency.
Znana dedna ali pridobljena nagnjenost k venski trombemboliji, kot so rezistenca na aktivirani protein C (APC; vključno s faktorjem V Leiden), pomanjkanje antitrombina-III, pomanjkanje proteina C, pomanjkanje proteina S.
Known hereditary or acquired predisposition for venous thromboembolism, such as APC-resistance, (including Factor V Leiden), antithrombin-III-deficiency, protein C deficiency, protein S deficiency;
Znana dedna ali pridobljena nagnjenost k venski trombemboliji, kot je rezistenca za aktivirani protein C (APC, activated protein C resistance), (vključno s faktorjem V Leiden), pomanjkanje antitrombina-III, pomanjkanje proteina C, pomanjkanje proteina S.
Known history of angioedema related to previous ACE inhibitor or ARB therapy (see section 4.4).
Anamneza angioedema zaradi predhodnega zdravljenja z zaviralcem ACE ali zaviralcem angiotenzinskih receptorjev (glejte poglavje 4.4).
known history of intracranial disease (neoplasm, arteriovenous malformation, aneurysm)
znano anamnezo intrakranialne bolezni (neoplazme, arteriovenske malformacije, anevrizme);
Known history of ischaemic stroke or transient ischaemic attack in the preceding 6 months
znana anamneza ishemične kapi ali prehodne ishemične napade v preteklih 6 mesecih, demenca.
Known HIV+ Partner Last 6 Months, N (%)
Znani partnerji s HIV+ v zadnjih 6 mesecih, N (%)
known hypersensitivity to rosiglitazone or to any of the excipients
z znano preobčutljivostjo za rosiglitazon ali katerokoli pomožno snov
Known hypersensitivity to sulphonamides (see also section 4.4).
znana preobčutljivost na sulfonamide (glejte tudi poglavje 4.4),
Known hypersensitivity to sulphonamides.
Znana preobčutljivost za sulfonamide.
Known hypersensitivity to the Raplixa active substances or to any of the excipients listed in section 6.1. Raplixa must not be applied intravascularly.
Znana preobčutljivost na zdravilno učinkovino ali katero koli pomožno snov, navedeno v poglavju 6.1. Zdravila Raplixa se ne sme dajati intravaskularno.
Known immunodeficiency syndrome.
Ugotovljen sindrom imunske pomanjkljivosti.
Known interactions with the following agents
znana interakcija s spodaj navedenim zdravilom
Known mechanisms of resistance to aztreonam mediated by mutation of chromosomal genes include: hyperexpression of the Class C beta-lactamase AmpC and up-regulation of the efflux pump
Znani mehanizmi odpornosti na aztreonam, ki ga povzroči mutacija kromosomskih genov, vključujejo: hiperekspresija betalaktamaze AmpC razreda C in zvišanje ravni protonske črpalke MexAB-OprM.
Known or suspected allergy to rabbits (see section 4.4)
Znana alergija na kunce ali sum nanjo (glejte poglavje 4.4).
Known or suspected biliary duct obstruction or sphincter of Oddi disease or dysfunction.
Znana ali domnevna zapora žolčevoda ali bolezen ali nepravilno delovanje Oddijevega sfinktra.
Known or suspected carcinoma of the breast
znani karcinom dojke ali sum nanj
Known or suspected right-sided infective endocarditis due to Staphylococcus aureus: Cubicin 6 mg/kg is administered once every 24 hours.
Dokazan infekcijski endokarditis desne strani zaradi bakterije Staphylococcus aureus ali sum nanj: Zdravilo Cubicin je treba dajati v odmerku 6 mg/kg vsakih 24 ur.
Known or suspected sex steroid-influenced malignancies (e.g., of the genital organs or the breasts).
Znane maligne bolezni ali sum nanje (npr. genitalnih organov ali dojk), zaradi vpliva steroidnih spolnih hormonov.
Known photo allergy or photo toxic reaction during treatment with fibrates or ketoprofen.
Znana fotoalergija ali fototoksična reakcija med zdravljenjem s fibrati ali ketoprofenom.
Known photoallergy or phototoxic reaction during treatment with fibrates or ketoprofen
Znana alergija na svetlobo ali fototoksična reakcija med zdravljenjem s fibrati ali ketoprofenom
Known photodermatoses of varying pathology and frequency, e.g. metabolic disorders such as aminoaciduria, idiopathic or immunological disorders such as polymorphic light reaction, genetic disorders such as xeroderma pigmentosum, and diseases precipitated or aggravated by exposure to sun light such as lupus erythematoides or phemphigus erythemtoides.
Znane fotodermatoze različne patologije in pogostnosti, npr. presnovne bolezni, kot so aminoacidurija, idiopatske ali imunološke bolezni, kot so polimorfne reakcije na svetlobo, genske bolezni, kot so pigmentna kserodermija, ter bolezni, ki jih izzove izpostavljenost sončni svetlobi ali se poslabšujejo zaradi take izpostavljenosti, kot so eritematozni lupus ali eritematozni pemfigus.
Known thrombophilic disorders (e.g., protein C, protein S, or antithrombin deficiency, see section 4.4).
Znane trombofilične motnje (npr. pomanjkanje proteina C, proteina S ali pomanjkanje antitrombina; glejte poglavje 4.4).
Known, past or suspected oestrogen-dependent malignant tumours (e.g., endometrial cancer).
Znani, od estrogenov odvisni maligni tumorji (npr. rak endometrija), sum nanje ali od estrogenov odvisni maligni tumorji v anamnezi.
Known, suspected, or past history of breast cancer.
Znan rak dojke, sum nanj ali rak dojke v anamnezi.
knows that any member of your family (parents, grandparents, brothers or sisters) died suddenly due to a heart problem or was born with heart problems;
če veste, da je kateri koli član vaše družine (starši, stari starši, bratje ali sestre) umrl nenadne smrti zaradi težav s srcem ali je bil rojen s srčnimi težavami;
KOGENATE Bayer
EU/1/00/143/005 KOGENATE
KOGENATE Bayer
EU/1/00/143/006 KOGENATE
KOGENATE Bayer 250 IU powder for solution for injection KOGENATE Bayer 500 IU powder for solution for injection KOGENATE Bayer 1000 IU powder for solution for injection KOGENATE Bayer 2000 IU powder for solution for injection KOGENATE Bayer 3000 IU powder for solution for injection
KOGENATE Bayer 250 i.e. prašek za raztopino za injiciranje KOGENATE Bayer 500 i.e. prašek in vehikel za raztopino za injiciranje KOGENATE Bayer 1000 i.e. prašek in vehikel za raztopino za injiciranje KOGENATE Bayer 2000 i.e. prašek in vehikel za raztopino za injiciranje KOGENATE Bayer 3000 i.e. prašek in vehikel za raztopino za injiciranje
Kogenate Bayer as a continuous infusion has also been studied in 15 patients with haemophilia A undergoing major surgery.
Zdravilo Kogenate Bayer so proučili tudi ob dajanju tega zdravila v obliki kontinuirane infuzije pri 15 bolnikih s hemofilijo A, pri katerih je bil opravljen večji kirurški poseg.
Kogenate Bayer can also be given continuously for up to seven days as an infusion (drip into a vein) in patients undergoing major surgery.
Zdravilo Kogenate Bayer se lahko daje tudi zaporedoma sedem dni kot infuzija (dajanje v veno po kapljicah) pri bolnikih, pri katerih je bil opravljen večji kirurški poseg.
KOGENATE Bayer can be used in children of all ages.
Zdravilo KOGENATE Bayer se lahko uporablja pri otrocih vseh starosti.
KOGENATE Bayer contains sodium
Zdravilo KOGENATE Bayer vsebuje natrij
Kogenate Bayer contains the active substance human coagulation factor VIII (octocog alfa).
Zdravilo vsebuje zdravilno učinkovino humani koagulacijski faktor VIII (oktokog alfa).
Kogenate Bayer given as an injection into a vein has been studied in 66 patients who had previously been treated with recombinant human coagulation factor VIII and 61 children who had not.
Zdravilo Kogenate Bayer, vbrizgano z injekcijo v veno, so proučevali pri 66 bolnikih, ki so bili predhodno zdravljeni z rekombinantnim koagulacijskim faktorjem VIII, in pri 61 otrocih, ki z njim predhodno niso bili zdravljeni.
Kogenate Bayer given at high dose has been studied to see whether it is effective in clearing antibodies against factor VIII from the blood (a process known as immune tolerance induction) so that treatment with factor VIII remains effective.
Zdravilo Kogenate Bayer v visokem odmerku so preučevali, da bi ugotovili, ali je učinkovito pri odstranjevanju protiteles za faktor VIII iz krvi (proces, znan kot indukcija imunske tolerance), tako da zdravljenje s faktorjem VIII ostane učinkovito.
Kogenate Bayer human coagulation factor VIII (octocog alfa)
Kogenate Bayer humani koagulacijski faktor VIII (oktokog alfa)
Kogenate Bayer is a powder and solvent that are mixed together to make up a solution for injection.
Zdravilo Kogenate Bayer sestavljata prašek in vehikel, ki se zmešata v raztopino za injiciranje.
Kogenate Bayer is given by injection into a vein lasting several minutes.
Zdravilo Kogenate Bayer se daje z nekajminutno injekcijo v veno.
Kogenate Bayer is intended for either short-term or long-term use.
Zdravilo je namenjeno kratkotrajni ali dolgotrajni uporabi.
KOGENATE Bayer is not likely to affect the fertility in male or female patients, as the active substance is naturally occurring in the body.
Ni verjetno, da bi zdravilo KOGENATE Bayer vplivalo na plodnost bolnikov in bolnic, saj je zdravilna učinkovina v telesu naravno prisotna.
Kogenate Bayer is similar to another medicine that was previously authorised in the European Union (EU) called Kogenate, but it is prepared differently so that there are no human-derived proteins in the medicine.
Zdravilo Kogenate Bayer je podobno drugemu zdravilu, ki je že bilo odobreno v Evropski uniji (EU), zdravilu Kogenate, vendar je pripravljeno drugače, in sicer tako, da v njem ni nobenih beljakovin človeškega izvora.
Kogenate Bayer is used for the treatment and prevention of bleeding in patients with haemophilia A (an inherited bleeding disorder).
Zdravilo Kogenate Bayer se uporablja za zdravljenje in preprečevanje krvavitev pri bolnikih s hemofilijo A (dedno motnjo strjevanja krvi).
Kogenate Bayer is used to correct the factor VIII deficiency by replacing the missing factor VIII, giving temporary control of the bleeding disorder.
Z zdravilom Kogenate Bayer se popravi pomanjkanje faktorja VIII tako, da se nadomesti manjkajoči faktor VIII, kar vzpostavi začasni nadzor nad krvavitvami.
Kogenate Bayer must not be used in people who are known to be hypersensitive (allergic) to human coagulation factor VIII or to any of the other ingredients.
Zdravila Kogenate Bayer ne smejo uporabljati osebe, ki so preobčutljive za (alergične na) humani koagulacijski faktor VIII ali katero koli drugo sestavino zdravila.
Kogenate Bayer should be started by a doctor who has experience in the treatment of haemophilia.
Zdravljenje z zdravilom Kogenate Bayer mora uvesti zdravnik, ki ima izkušnje z zdravljenjem hemofilije.
Kolbam 250 mg hard capsules cholic acid
Kolbam 250 mg trde kapsule holna kislina
Kolbam 250 mg hard capsules.
Kolbam 250 mg trde kapsule
Kolbam 50 mg hard capsules cholic acid
Kolbam 50 mg trde kapsule holna kislina
Kolbam 50 mg hard capsules Kolbam 250 mg hard capsules cholic acid
Kolbam 50 mg trde kapsule Kolbam 250 mg trde kapsule holna kislina
Kolbam 50 mg hard capsules.
Kolbam 50 mg trde kapsule
Kolbam has been authorised under ‘exceptional circumstances’.
Zdravilo Kolbam je pridobilo dovoljenje za promet „v izjemnih okoliščinah“.
Kolbam is authorised for the life-long treatment of adults and children from one month of age who cannot produce enough primary bile acids such as cholic acid due to certain genetic abnormalities that result in a lack of the following liver enzymes: sterol 27-hydroxylase; 2-methylacyl-CoA racemase; or cholesterol 7-hydroxylase.
Zdravilo Kolbam se uporablja za vseživljenjsko zdravljenje odraslih in otrok, starejših od enega meseca, ki zaradi genetskih nepravilnosti, katerih posledica je pomanjkanje jetrnih encimov sterol 27-hidroksilaze, 2-metilacil-CoA racemaze ali holesterol 7hidroksilaze niso zmožni tvoriti dovolj primarnih žolčnih kislin, kot je holna kislina.
Kolbam is indicated for the treatment of inborn errors in primary bile acid synthesis due to Sterol 27- hydroxylase (presenting as cerebrotendinous xanthomatosis, CTX) deficiency, 2- (or -) methylacyl- CoA racemase (AMACR) deficiency or Cholesterol 7-hydroxylase (CYP7A1) deficiency in infants, children and adolescents aged 1 month to 18 years and adults.
Zdravilo Kolbam je indicirano za zdravljenje prirojenih napak v sintezi primarnih žolčnih kislin, do katerih pride zaradi pomanjkanja sterol 27-hidroksilaze (ki se kaže kot cerebrotendinozna ksantomatoza, CTX), pomanjkanja 2- (ali -) metilacil-CoA racemaze (AMACR) ali pomanjkanja holesterol 7-hidroksilaze (CYP7A1), pri dojenčkih, otrocih in mladostnikih, starih od enega meseca do 18 let, ter pri odraslih.
Kolbam is provided as hard capsules.
Zdravilo Kolbam je na voljo v obliki trdih kapsul.
Kolbam is used to treat these ‘inborn errors of bile acid synthesis’.
Zdravilo Kolbam se uporablja za zdravljenje teh „prirojenih okvar sinteze žolčnih kislin“.
Kolbam was investigated in one main study involving 52 patients with inborn errors in primary bile acid synthesis, including 7 patients who lack either sterol 27-hydroxylase, 2-methylacyl-CoA racemase or cholesterol 7-hydroxylase.
Zdravilo Kolbam so proučevali v eni glavni študiji, v kateri je sodelovalo 52 bolnikov s prirojenimi napakami v sintezi primarnih žolčnih kislin, vključno s sedmimi bolniki, ki jim je primanjkovalo sterol 27-hidroksilaze, 2-metilacil-CoA racemaze ali holesterol 7hidroksilaze.
Komboglyze 2.5 mg/1,000 mg film-coated tablets
Komboglyze 2,5 mg/1000 mg filmsko obložene tablete
Komboglyze 2.5 mg/1,000 mg film-coated tablets (‘tablets’) are pale yellow to light yellow and oval, with “2.5/1000” printed on one side and “4247” printed on the other side, in blue ink.
Zdravilo Komboglyze 2,5 mg/1000 mg filmsko obložene tablete (»tablete«) so bledorumene do svetlo rumene ovalne tablete, ki imajo z modrim črnilom na eni strani natisnjeno oznako "2.5/1000" in na drugi strani oznako "4247".
Komboglyze 2.5 mg/1,000 mg film-coated tablets saxagliptin/metformin hydrochloride
Komboglyze 2,5 mg/1000 mg filmsko obložene tablete saksagliptin/metforminijev klorid
Komboglyze 2.5 mg/850 mg film-coated tablets (‘tablets’) are light brown to brown and round, with “2.5/850” printed on one side and “4246” printed on the other side, in blue ink.
Zdravilo Komboglyze 2,5 mg/850 mg filmsko obložene tablete (»tablete«) so svetlo rjave do rjave okrogle tablete, ki imajo z modrim črnilom na eni strani natisnjeno oznako "2.5/850" in na drugi strani oznako "4246".
Komboglyze 2.5 mg/850 mg film-coated tablets.
Komboglyze 2,5 mg/850 mg filmsko obložene tablete
Komboglyze combines two antihyperglycaemic medicinal products with complementary mechanisms of action to improve glycaemic control in patients with type 2 diabetes: saxagliptin, a dipeptidyl peptidase 4 (DPP4) inhibitor, and metformin hydrochloride, a member of the biguanide class.
Zdravilo Komboglyze je kombinacija dveh antihiperglikemičnih učinkovin s komplementarnima mehanizmoma delovanja, ki izboljšata urejenost glikemije pri bolnikih s sladkorno boleznijo tipa 2: saksagliptina, zaviralca dipeptidil peptidaze 4 (DPP-4) in metforminijevega klorida, ki spada v skupino bigvanidov.